Related Experiment Video
Updated: Aug 21, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
CARM1: an epigenetic brake on cDC1-mediated antitumor immunity
1Department of Immunology, Center for Immunotherapy, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China.
Abstract:
The underlying mechanism of tumor microenvironment-induced dysfunction of conventional type 1 dendritic cells (cDC1) remains unclear. Zhang et al. identify transforming growth factor β-driven coactivator-associated arginine methyltransferase 1 (CARM1) as an epigenetic inhibitor of cDC1 cross-presentation. CARM1 is a cell-intrinsic brake, and its inhibition represents a multi-pronged tumor immunotherapy strategy.
Insights
Tumor microenvironments impair dendritic cells (cDC1) via CARM1. Inhibiting CARM1, an epigenetic regulator, may enhance anti-tumor immunity and immunotherapy strategies.
Area of Science:
- Immunology
- Epigenetics
- Cancer Biology
Background:
- The tumor microenvironment (TME) can suppress anti-tumor immune responses.
- Conventional type 1 dendritic cells (cDC1) are crucial for initiating adaptive immunity against tumors.
- The mechanisms by which the TME causes cDC1 dysfunction are not fully understood.
Related Concept Videos
Abnormal Proliferation
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Epigenetic Regulation
Inhibition of Cdk Activity
Inhibition of CDK Activity
